Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.53 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.53 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27796132 | 0.87 | ALDH1A1 (0.43) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL20767517 | 0.85 | FAAH (0.43) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL3728677 | 0.84 | LTA4H (0.52) | ALDH1A1CYP2C19HTTFAAHCNR2 | |
| SCHEMBL20767525 | 0.82 | CCNB2 (0.58) | ERN1ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL28749394 | 0.81 | ERN1 (0.44) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1494208 | 0.81 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL3266741 | 0.81 | ERN1 (0.50) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL2875694 | 0.81 | ALDH1A1 (0.50) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL17821776 | 0.80 | ERN1 (0.53) | ERN1TLR2TLR1TLR6CYP2C19 | |
| SCHEMBL21360162 | 0.79 | ERN1 (0.47) | ERN1TLR2TLR1TLR6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257027-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS (US) | 2025-08-14 | — | — | US | disclosed |
| US-12269798-B2 | Second generation GRP94-selective inhibitors | UNIVERSITY OF KANSAS (US) | 2025-04-08 | — | — | US | disclosed |
| US-20210300872-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS | 2021-09-30 | — | — | US | disclosed |
| US-20210300872-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS | 2021-09-30 | — | — | US | disclosed |
| US-11028041-B2 | Second generation GRP94-selective inhibitors | UNIVERSITY OF KANSAS (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028041-B2 | Second generation GRP94-selective inhibitors | UNIVERSITY OF KANSAS (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200190017-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS | 2020-06-18 | — | — | US | disclosed |
| US-20200190017-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS | 2020-06-18 | — | — | US | disclosed |
| WO-2019040792-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040792-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-1150954-B1 | ANTI-IMFLAMMATORY INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-10-13 | — | — | EP | disclosed |
| CN-1505603-A | Substituted benzoic ac id derivatives exhibiting nf-kappab inhibiting activity | ��һ��������ҩ��ʽ���� | 2004-06-16 | — | — | CN | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| CN-1460097-A | NF-kB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY SEIYAKU CO LTD (JP) | 2003-12-03 | — | — | CN | disclosed |
| US-6569888-B1 | Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis | ASTRAZENECA AB (SE) | 2003-05-27 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| CN-1351591-A | Anti-inflammatory indole derivatives | ASTRAZENECA AB (SE) | 2002-05-29 | — | — | CN | disclosed |
| EP-1150954-A1 | ANTI-IMFLAMMATORY INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046198-A1 | ANTI-INFLAMMATORY INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | ERN1 1774/4885TLR2 4537/4885TLR1 3900/4885 |
| US-12269798-B2 | Second generation GRP94-selective inhibitors | HSP90B1, HSP90AB2P, HSPE1 | ERN1 3410/4885TLR2 4602/4885TLR1 4827/4885 |
| US-20210300872-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | HSP90B1, HSP90AB2P, HSPE1 | ERN1 3410/4885TLR2 4602/4885TLR1 4827/4885 |
| US-20250257027-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | HSP90B1, HSP90AB2P, HSPE1 | ERN1 3392/4885TLR2 4618/4885TLR1 4834/4885 |
| US-11028041-B2 | Second generation GRP94-selective inhibitors | HSP90B1, HSP90AB2P, HSPE1 | ERN1 3392/4885TLR2 4618/4885TLR1 4834/4885 |
| US-20200190017-A1 | SECOND GENERATION GRP94-SELECTIVE INHIBITORS | HSP90B1, HSP90AB2P, HSPE1 | ERN1 3392/4885TLR2 4618/4885TLR1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.